Document is current

Article History

Received: 16 July 2024

Accepted: 29 October 2024

First Online: 13 November 2024

Declarations

:

: Not applicable.

: Not applicable.

: Evren Alici is a founder of XNK therapeutics, Vycellix, VyGenBio, and Fuse therapeutics. EA also serves as an advisor to Artiva, Avectas, Virocell, and Sorrento therapeutics. All relationships have been reviewed and managed by Karolinska University Hospital and Karolinska Institute in accordance with its conflict-of-interest policies. Aimee Merino has no conflicting interests. Michael O’Dwyer is a founder and board member at ONK Therapeutics and may hold stocks/stock options in the company. Rizwan Romee reports research grants from Crispr Therapeutics and Skyline Therapeutics and serves on the scientific advisory board of Glycostem Therapeutics and xNK Therapeutics. Eric L. Smith has consulted for ArsenalBio, Blackstone Life Sciences, Chroma Medicine, Clade Therapeutics, Eureka Therapeutics, ImmuneBridge, Legend Biotech, Overland Pharmaceuticals, Prdicta Biosciences and Sana Biotech. ELS is an inventor on licensed patents and receives royalties from Bristol Myers Squibb and Sanofi. ELS is on the Scientific Advisory Boards of Bristol Myers Squibb, Chimeric Therapeutics and Sanofi. ELS holds equity in Predicta Biosciences and receives research funding from Sanofi. Edward Briercheck reports a Conquer Cancer Foundation Global Oncology Young Investigator Award and a Fulbright Scholar Award. Eric Vivier and Laurent Gauthier are employees of Innate Pharma and may hold stocks/stock options of Innate Pharma. Kamlesh Bisht, Marielle Chiron, Alexandre Desjonqueres, Rob Igarashi, and Helgi van de Velde are employees of Sanofi and may hold stock/stock options of Sanofi.